Ipsen announced results from the only prospective, head-to-head Phase IV DIRECTION trial comparing Dysport (abobotulinumtoxinA) to Botox (onabotulinumtoxinA) in adults living with upper limb spasticity (ULS) will be presented as a late-breaking presentation… read more.
People who work fewer hours each year appear to have a lower risk of obesity, according to an Australian study presented at the European Congress on Obesity in… read more.
The EU drug watchdog, the European Medicines Agency (EMA), has given the green light for eight new medicines at its May meeting. This brings to 36 the number… read more.
AbbVie has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of Maviret (glecaprevir/pibrentasvir), an oral… read more.
The path to wiping out cervical cancer looks increasingly clear – at least for high-income countries with strong uptake of the human papillomavirus (HPV) vaccine and cervical screening…. read more.
The European Medicines Agency (EMA) has been nominated for the European Ombudsman Award for Good Administration. The Agency’s One Health Instagram account is shortlisted in the ‘Excellence in… read more.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today… read more.
Pfizer announced that the European Commission has granted marketing authorization to expand the approved indication for Hympavzi (marstacimab) to include patients 12 years of age and older weighing… read more.
People born with heart defects experience their first acute heart attack at a significantly earlier age than others, according to a new national study from Lund University in… read more.
The European Medicines Agency (EMA) has unveiled a new communications effort designed to inform evidence-based decision-making. Vaccine Essentials offers healthcare professionals accessible summaries of how the quality, safety… read more.
Ipsen announced the presentation of new late-breaking results from the ELATIVE® Phase III trial and two real-world studies at the European Association for the Study of the Liver (EASL)… read more.
Boehringer Ingelheim’s Jascayd (nerandomilast) has been recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for the treatment… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
